@Bedford -
I also noted last week that they filed to increase their Phase I MT1988 trial from 38 up to 76 participants. A little bit odd to do that mid trial.
19/02/2025: The following amendments were made:
1. The overall study end date was changed from 16/03/2025 to 30/06/2025.
2. The target number of participants was changed from 38 to up to 76.
3. The recruitment end date was changed from 03/03/2025 to 15/04/2025 |
My linkedin had a new post today about Monument Therapeutics they have another 850k for the schizophrenia development. This must be quite lucrative pipeline they certainly don't seem to have any issues fundraising No mention regarding Cam Cog or dilution. |
For an overview of what Winterlight Labs does, how it does it and how long it takes to validate any technology in the CNS space and thus the size of the moat CANTAB and Winterlight have. Then this YouTube interview with some of the founding team is worth watching, it was posted a few weeks ago. |
Having looked a little more, my suspicion above is highly likely to be correct.
In the RNS, they say: "The approach builds on recent positive exploratory results using several of these assessments in a Phase III clinical trial of patients with schizophrenia³."
Footnote ³ is:
"Horan, William P., et al. 'The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase III Trials.' American Journal of Psychiatry (2024)."
This paper, published by BMS, showed that by pooling the CANTAB data from the two Phase III trials, they were able to find a signal of cognitive improvement in a subgroup that had significant cognitive deficits prior to the trial start. These results were independent of the effect on psychotic symptoms. |
I suspect today's RNS has something to do with BMS and its recently approved COBENFY (KarTX). Last month, Cambridge Cognition congratulated BMS on its approval and noted that CANTAB data had been used to conduct certain post-hoc analysis.
If I am right and this is for an upcoming BMS trial or trials and this is using the a combination of tests already approved via CANTAB's FDA approval this should not be a long process. i.e. Months not years. Having a proprietary primary endpoint in Schizophrenia would come with significant revenue from BMS and many others. |
 The link below highlights the longer term potential of Cambridge Cognition in the healthcare setting. Leaving aside for the moment the obvious opportunity in Alzheimers, they have a substantial number of validated biomarkers under development that can help identify clinical issues ranging from psychosis to hepatic encephalopathy.
Interestingly, many of these biomarkers are multimodal and require two or more of Cambridge Cognition's capabilities. There are very few, if any, other organisations that can achieve this in-house without collaboration.
This link directs you to a recent paper published in the Journal of Aging Research and involves Monument Therapeutics (Cambridge Cognition spin out). Essentially, the paper reveals that by using a combination of two hippocampal-focused tests from Cambridge Cognition (spatial working memory and paired-associates learning) before a major operation, it was possible to identify a subset of the population with double the likelihood of being discharged to a place other than home, a greater likelihood of developing postoperative delirium, and longer hospital stays.
Monument Therapeutics are trying to identify this population for treatment with their prophylactic. However, this would also clearly have other benefits in a clinical setting as based on two quick tests with an IPAD they can identify patients who are more likely to require enhanced post operative care pathways. |
No problems now anyway,dont know what that was all about (my name changed from Tom111) some tech probs. |
Just not right that you can only buy £100 but sell £50,000. Yep I wouldn’t be selling at 60p but the price should reflect the total lack of liquidity on the buy side. The Noddy Market Maker should do as their title suggests or retire to Toytown. |
Interesting idea Bedford:) not sure it would be anyone but Pi. Ints will be expecting multiples of current Sp I would have thought. Not that many shares in circulation even after the last placing. Results a bit late this year. I think 2020 was the last time they were in Feb |
Market makers need to push up the share price to 60 pence and let's smoke out some sellers. |
Market maker there to set a price and provide sufficient (or at least some) liquidity. Not to act in collusion. |
This has been going on for a whole week somethinggoing on in the background? |
I thought there was a minimum deal size a market maker was obliged to meet? Yesterday I couldn’t buy £70 worth!!! Got a price to sell £50k worth though. This is not market making. I’ve got a far better way of describing it! |
When I saw thr RNS titled Board Appointment,I assumed it was for the appointment of a CEO or CFO.
Perhaps the current arrangement is working well enough that they can take their time in making an appointment. |
I tested for a buy of £100 Bedford just to see,not a bean so someone is mopping up. imo |
Nice chart setup. Above the 200EMA for the first time since September 2022, and has held. Fundamentals and Director activity support the technicals. Monument also making steady progress. By far the most promising it's looked for a couple of years. |
Tom. I've had exactly the same issue tried to get 2.5k shares through Jarvis investments. They couldn't fulfill the order volume, luckily topped up properly a while back at the lows.
We made find really large upward movement in the share price when stock becomes available.
Somebody is hoovering up every available share. |
WIth no shares available for the last few days i can only assume that the next trading update will be very positive and the share price imo will be up significantly |
It appears that the Actinogen announcement isn't the major news that the Companies actions have been suggesting, recall the recent job listings for "expression of interest" for NEW clinical positions last month.
Whatever this event might be, it is reasonable to assume it has the potential to push revenues beyond the GBP 13.5mn achieved in 2023, which they were able to service with their existing clinical/scientific resources. Line of sight to GBP 14/15 mn of revenues for either this year or next would have a significant and very rapid impact on the share price. |
Agree we are now winning. Utilizing our full suite of products was evident in the RNS. Although Stork has departed he appears to have paved the way for a very profitable outcome for shareholders. |
The real significance of yesterday's RNS has only just dawned on me. Cambridge Cognition won all the cognitive measurement, data capture, and quality control work for the entire trial, even though CANTAB is only a secondary endpoint. The primary endpoint, CDR-SB, must be administered by a rater, usually a clinical psychologist.
This is significant because, before the acquisition of Clinpal and Winterlight (24 months ago) and subsequent product development, Cambridge Cognition could have only provide the secondary endpoint for this trial. It is interesting and significant that Cambridge Cognition replaced Cogstate, which had provided the non-eCOA work in earlier trials. Normally, I would not pay too much attention to this; however, in Alzheimer's Disease (AD), Cogstate is the dominant player and has digital offerings so this is significant.
This hints at a significant increase in the potential opportunity set in other trials/indications where rater based scales are used as primary endpoints and AQUA is relevant such as PANNS, ADAS-COG, HAM-A, HAM-D etc and where a CANTAB battery may only be an exploratory or secondary endpoint. |
Not an impressive reponse at Niox this morning Simon the S/C seems on the high side,better prospects here i would have thought GL |
Hi Tom. I certainly hope so now we are both out of Niox? Strange market reaction to their results today, but Pretty much what I expected. You got into Renx too? Bit of a gamble as here. At least we are getting a bit more news flow now and with appointment of new CEO looming and results maybe better than expected(guessing obviously) Sometimes it’s better to juggle things about a bit. |
Thanks earwacks looks as if its going to be a winner.M/C only 16M as well |
@40fathoms
Thanks for that piece expanding the RNS today, very interesting |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
